About the Authors
- Ahmed E. Enayetallah
-
* E-mail: Ahmed.Enayetallah@pfizer.com
Affiliation Compound Safety Prediction Group, Pfizer Inc., Groton, Connecticut, United States of America
- Daniel Ziemek
-
Affiliation Computational Sciences Center of Emphasis, Pfizer Inc., Cambridge, Massachusetts, United States of America
- Michael T. Leininger
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- Ranjit Randhawa
-
Affiliation Computational Sciences Center of Emphasis, Pfizer Inc., Cambridge, Massachusetts, United States of America
- Jianxin Yang
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- Tara B. Manion
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- Dawn E. Mather
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- William J. Zavadoski
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- Max Kuhn
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- Judith L. Treadway
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- Shelly Ann G. des Etages
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- E. Michael Gibbs
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
- Nigel Greene
-
Affiliation Compound Safety Prediction Group, Pfizer Inc., Groton, Connecticut, United States of America
- Claire M. Steppan
-
Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America
Competing Interests
The authors have read the journal's policy and have the following conflicts: The work has been funded by Pfizer Inc. as part of DGAT1 therapeutic targeting program and the authors are/were paid employee of the funder, Pfizer Inc. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SAdE EMG CS. Performed the experiments: ML JY TM DM WZ. Analyzed the data: AE DZ ML JY MK CS. Contributed reagents/materials/analysis tools: AE DZ RR MK NG. Wrote the paper: AE DZ ML CS. Designed the experiments: DM JT.